Sustained Release of Tissue Factor Following Thrombosis of Lower Limb Trauma
|
|
- Edwina Montgomery
- 6 years ago
- Views:
Transcription
1 Original Article Sustained Release of Tissue Factor Following Thrombosis of Lower Limb Trauma Clinical and Applied Thrombosis/Hemostasis 2014, Vol. 20(7) ª The Author(s) 2014 Reprints and permission: sagepub.com/journalspermissions.nav DOI: / cat.sagepub.com Jeanine M Walenga, PhD 1,2, Phoebe C Kaiser 1, M Margaret Prechel, PhD 1,2, Debra Hoppensteadt, PhD 2, Walter P Jeske, PhD 1,2, Frank Misselwitz, MD 3, Peter Bacher, MD 4, Michael R Lassen, MD 5, and Jawed Fareed, PhD 2 Abstract This study was undertaken to provide evidence for the mechanism of venous thromboembolism (VTE) in healthy patients with minor lower limb injury (fracture; Achilles tendon rupture) that was medically managed with plaster cast/brace immobilization. The Plaster Cast clinical trial provided a unique opportunity to identify the natural history of VTE using placebo-controlled patients (n ¼ 183) with validation of the mechanism using the low-molecular-weight heparin (LMWH; reviparin)-treated patients (n ¼ 182). Confirmed VTE in this population was associated with a burst of tissue factor release (and a minor fibrinolytic deficit) leading to thrombin generation that was sustained at least 5 weeks, greater with fractures than with soft-tissue injuries and greater with surgery than with conservative treatment. The root cause likely involves platelet/leukocyte activation (inflammation) rather than endothelial cell injury. Thromboprophylaxis with a low dose of LMWH reduced thrombin generation, with patients undergoing surgery benefitting the most. Keywords lower limb, trauma, immobilization, venous thrombosis, low-molecular-weight heparin, reviparin, tissue factor Introduction Venous thromboembolic events are a common, life-threatening complication of major trauma. Without prophylaxis, patients with major trauma (including bodily injury from accidents and surgery) have a risk for venous thromboembolism (VTE) that exceeds 50%. 1,2 Pulmonary embolism (PE) is the third most common cause of death in patients with major trauma who survive beyond the first day. 1,3 These observations clearly place patients with major trauma in the high-risk group for VTE. Patients with trauma having multiple injuries or with isolated lower extremity fractures have a higher risk of VTE than those with single-system, nonorthopedic injuries. 1,4,5 Specific risk factors that were independently associated with an increased incidence of thromboembolism included lower extremity or pelvic fracture, the need for a surgical procedure, increased age, femoral venous line, prolonged immobilization, and duration of hospital stay. In studies of only isolated lower limb trauma, patients with below-knee injuries and immobilization have a 10% to 35% incidence of deep vein thrombosis (DVT) depending on the type and severity of injury, and they have a risk of clinical PE in the range of 0.4% to 2.1% The Plaster Cast clinical study was conducted by Lassen et al and published in At the time this investigation was conceived (1996), consensus guidelines stated that patients with isolated lower limb trauma and immobilization are at moderate risk of DVT, but because of the heterogeneity of patient groups and lack of clear evidence, routine prophylaxis was not recommended The standard of care for patients with lower limb injuries in most countries at that time was no prophylaxis or only short-term prophylaxis in the perioperative setting. The Plaster Cast clinical study was carried out to confirm the hypothesis that patients treated by functional immobilization with a plaster cast after lower leg trauma require general long-term thromboprophylaxis. 13 This study evaluated the efficacy and safety of the low-molecular-weight (LMW) heparin reviparin (Clivarin; Knoll, Ludwigshafen, Germany), 1 Department of Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL, USA 2 Department of Pathology, Loyola University Medical Center, Maywood, IL, USA 3 Cardiovascular and Coagulation Therapeutics, Bayer Healthcare, Wuppertal, Germany 4 Global Pharmaceutical R&D, AbbVie, North Chicago, IL, USA 5 Spine Center, Glostrup Hospital, University of Copenhagen, Denmark Corresponding Author: Jeanine M Walenga, Cardiovascular Institute, Loyola University Medical Center, Building 110, Room 5226, 2160 S. First Avenue, Maywood, IL 60153, USA. jwaleng@luc.edu
2 Walenga et al 679 compared to placebo, for the prevention of VTE in patients having an isolated leg injury such as lower extremity fracture or Achilles tendon rupture (ATR). The clinical outcomes demonstrated an incidence of VTE of 19% in patients receiving placebo (including 2 cases of PE) that was significantly reduced to 9% in patients receiving reviparin (P ¼.01). At the time the Plaster Cast clinical study was ongoing, we partnered with the Danish clinical investigators to further the appreciation and understanding of the natural history/ pathophysiology of VTE associated with isolated lower limb trauma. For the patients of the Plaster Cast clinical study, markers of hemostatic activation were analyzed over time following injury. The obtained data were further analyzed in terms of patients who did and did not receive thromboprophylaxis with the LMW heparin reviparin as a means to validate the identified pathophysiological mechanism. Having a placebo arm in this study provided a unique set of patients to allow such an investigation. This substudy of the Plaster Cast clinical study is described here. Materials and Methods Clinical Study The Plaster Cast clinical study was a prospective, randomized, double-blind, placebo-controlled, parallel group comparison conducted from April 1997 through September 1999 in 6 Danish hospitals. 13 All patients had a lower extremity fracture or an ATR that required at least 5 weeks of functional (ambulatory) immobilization in a plaster cast or brace. They were otherwise healthy. All displaced fractures were treated surgically by open reduction and internal fixation before immobilization. Other fractures were treated conservatively. The ATRs were operatively sutured if it was locally preferred. All patients gave written informed consent for enrollment into the study. Patients were randomized to either subcutaneous LMW heparin (1750 anti-factor Xa [FXa] units once daily reviparin [Clivarine]) or placebo (saline) administered for a duration of 5 to 6 weeks. Of the 371 enrolled patients who had evaluable venograms, 183 were assigned to reviparin and 188 to placebo. Patients who had undergone surgery before randomization were allowed to receive other heparin prevention but not for more than 4 days prior to enrollment. Mean time from surgery to randomization was days in both the groups. Bilateral ascending phlebography was performed to detect DVT on the day the brace was removed in all patients. The DVT was confirmed if present on the phlebogram with a constant intraluminal filling defect, or a constant nonvisualization of a proximal vein in the presence of a sudden cutoff, on at least 2 projections. Compression ultrasound could be used for confirmation of the diagnosis only in patients with symptoms of DVT. In this case, an objective documentation (picture) was required. A DVT was considered to be confirmed by compression ultrasound if there was noncompressibility of the popliteal vein in the popliteal fossa or of the femoralveininthegroin.apehadtobeconfirmedbyventilation perfusion lung scan present with a perfusion defect of at least 75% of segmental size with a normal ventilation at the spot or pulmonary angiography present with an intraluminal filling defect or a sudden cutoff of a vessel of 2.5 mm in diameterormore. Exclusion criteria included present VTE, diastolic blood pressure higher than 100 mm Hg, systolic blood pressure higher than 200 mm Hg, concomitant heparin or LMW heparin, pretreatment and/or any concomitant medication with fibrinolytics or vitamin K antagonists, or myocardial infarction within 3 months of enrollment. Blood Samples and Hemostatic Activation Markers Blood specimens were collected on patients at the clinical sites on the day of randomization (baseline) prior to any medical intervention, on day 10 to 14 after the injury occurred, and on the day of the removal of the cast/brace (postbrace) approximately 5 to 6 weeks after injury. Citrated whole blood was collected, immediately prepared for platelet-poor plasma, and stored at 80 C. Directly following all clinical evaluations, plasmas of all patients were shipped frozen by overnight delivery to Loyola University. Analyses were performed during the subsequent weeks following receipt of the samples. Quantitative determination of hemostatic activation markers was made by commercial enzyme-linked immunosorbent assays: thrombin antithrombin complex (TAT; Enzygnost TAT Dade Behring, Marburg, Germany), tissue factor (TF) antigen (Imubind, American Diagnostica, Greenwich, Connecticut), soluble thrombomodulin (TM; Imubind, American Diagnostica), plasminogen activator inhibitor type 1 (PAI-1) antigen (Asserachrom, Diagnostica Stago, Asnieres, France), soluble P-selectin (R&D; Minneapolis, Minnesota), and TF pathway inhibitor (TFPI; Imubind, American Diagnostica). Laboratory personnel were blinded to treatment and clinical outcomes of patients. The Asserachrome HPIA kit (Stago Asnieres, France) was used to detect antibodies to the complex of platelet factor 4 and heparin (heparin-induced thrombocytopenia [HIT] antibodies). All assays were performed according to the manufacturers instructions with additional controls included in each run. Normal ranges for each assay were determined by the laboratory prior to evaluating the study specimens. Statistical Analyses The hemostatic biomarker data are depicted as interquartile ranges using box plots since the data was not normally distributed. The median is depicted as the horizontal line within the box, the 25th and 75th percentiles (interquartile range) are the lower and upper borders of the box, and the 10th and 90th percentiles are the lower and upper whiskers. Data mean values areindicatedbyastar.theupperlimitofthenormalreference range is indicated by a line across the figure. Statistical significance was determined using the Wilcoxon signed-rank test for within-group comparisons between time
3 680 Clinical and Applied Thrombosis/Hemostasis 20(7) Table 1. Incidence of Venous Thrombosis in Patients of the Plaster Cast clinical study. VTE/Total (%) 10.0 All patients 52/371 (14.0) Placebo 35/188 (18.6) a Reviparin 17/183 (9.3) Abbreviation: VTE, venous thromboembolism. a Includes 2 pulmonary embolisms. 7.0 Table 2. Venous Thrombosis in Patients of the Plaster Cast Clinical Study Categorized by Type of Treatments and Injury. a VTE/Total, (%) Placebo Reviparin VTE (%) VTE (%) Surgery þ immobilization 28/199 (14.1) 21/28 (75.0) 7/28 (25.0) Immobilization 24/166 (14.5) 14/24 (58.3) 10/24 (41.7) Fracture 43/289 (14.9) 29/43 (67.4) 14/43 (33.6) Achilles tendon rupture 9/74 (12.2) 6/9 (66.7) 3/9 (33.3) TAT; ng/ml Abbreviation: VTE, venous thromboembolism. a Patients undergoing surgery to correct a lower limb injury were at the highest risk of developing a VTE event points or the U test (Mann, Whitney, and Wilcoxon) for comparisons between groups, performed as a 2-tailed test. P values<.05wereconsideredtobestatistically significant. 14 The Sigma Stat (SPSS; Chicago, Illinois) program for Windows was used for all statistical analyses. Results In this substudy of the Plaster Cast study, data of patients were analyzed in 2 ways. First, the data of the placebo group and the baseline data of the reviparin group were used to determine the natural history of thrombosis generation in this population. Second, the data of the reviparin group were used to validate the identified mechanism of thrombogenesis. The patients enrolled in the Plaster Cast study were healthy and active. The median age of patients was 47 years; 52% were male. There were no significant differences in risk factors for vascular disease between the group treated with reviparin and the group treated with placebo, except for smoking (47% placebo group vs 36% reviparin group). Complete demographics are provided in the publication of the clinical trial. 13 The overall rate of venous thromboembolic events (DVT confirmedbyphlebographyonthedayofthebraceremoval or PE confirmed by ventilation perfusion lung scan or pulmonary angiography) was 14.0% (18.6% in the placebo group and 9.3% in the reviparin group, Table 1). All DVTs were in the injured leg; there were 2 PEs in the placebo group. When the patients of the placebo group were subdivided by surgery or no surgery prior to immobilization and by type of injury (fracture or ATR), the patients who underwent surgery to correct lower leg trauma were found to be at the highest risk to develop thrombosis (75% vs 58% for patients who did not have surgery; 67% for either fracture or ATR; Table 2). Natural History of Thrombogenesis Baseline Day Post Brace Figure 1. Thrombin generation in patients with leg trauma during the recovery period. The TAT levels were in the high normal range at the time of injury (n ¼ 183 placebo-treated patients) with certain patients showing excessively high levels. Levels consistently decreased over the 5-week period in all patients (median values: P <.001 baseline vs day 10-14; P <.001 day vs post-brace). TAT indicates thrombin antithrombin complex. Thrombin antithrombin complex. Thrombin antithrombin complex (TAT), a marker of thrombin generation, was normal (<4.0 ng/ml) at the time of injury in most patients (Figure 1 shows all placebo-treated patients [n ¼ 183]). The median level was 1.90 ng/ml ( ng/ml; interquartile range). However, the mean level was 4.06 ng/ml with a number of values higher than 10 ng/ml. Throughout the postinjury recovery period, mean and median TAT levels progressively decreased (P <.001) such that nearly all patients had TAT values <4.0 ng/ml at the time the brace was removed. Classified by severity of injury (ie, medical condition defined by type of injury and treatment), the median TAT level at baseline was 2.09 ng/ml (n ¼ 289; ng/ml) in the fracture group and 0.78 ng/ml (n ¼ 76; ng/ml) in the ATR group (P <.001; Figure 2). Mean TAT levels were also higher in the fracture group (4.31 ng/ml) than in the ATR
4 Walenga et al 681 TAT; ng/ml All patients group (2.76 ng/ml). Some patients in the fracture group had TAT levels as high as 40, 60, and 100 ng/ml. Patients who underwent surgery prior to immobilization (n ¼ 199) had a higher TAT mean value level than patients who did not underwent surgery (n ¼ 166), 4.62 ng/ml Fracture Achilles Surgery No surgery tendon rupture Figure 2. Thrombin generation in patients with leg trauma categorized by severity of injury. Although in general the patients with leg trauma (baseline samples on all patients; n ¼ 365) had TAT levels within the normal range, patients with fracture and/or surgery had highly elevated levels. Classified by type of injury, median TAT levels were higher in the fracture group than in the ATR group (P <.001). Classified by type of treatment, TAT levels were higher in patients of the surgery group (median values: P ¼.113 vs conservative nonsurgical treatment). TAT indicates thrombin antithrombin complex; ATR, Achilles tendon rupture. TAT; ng/ml Baseline Day Post Brace No thrombosis Thrombosis Figure 3. Analysis of thrombin generation in the VTE group of patients with leg trauma. Compared to the non-vte group (n ¼ 313), median TAT levels were higher in the VTE group (n ¼ 52) on day 10 to 14 (P ¼.012) and at the postbrace time period (P ¼.035). VTE indicates venous thromboembolism; TAT, thrombin antithrombin complex. TAT; ng/ml Baseline Day Surgery-Placebo Conserva ve treatment- Placebo Post Brace (median 2.05 ng/ml; ng/ml) compared to 3.30 ng/ml (median 1.59 ng/ml; ng/ml; Figure 2). The highest TAT values in the entire study population were found in the surgical patients with VTE. Because of a wide range of values, the difference between these 2 groups was not significant (P ¼.113). The levels of TAT were not significantly different at baseline for the VTE group (n ¼ 52) and non-vte group (n ¼ 313; Figure 3). The TAT levels reduced over time for patients who did not experience a thrombotic event. The median TAT level in the non-vte group was 1.84 ng/ml ( ng/ ml) at the time of injury, 1.02 ng/ml ( ng/ml) at day 10 to 14, and 0.69 ng/ml ( ng/ml) at the time the brace was removed, representing a significant change from time point to time point (P <.001). In contrast, TAT levels in patients with VTE remained elevated at day 10 to 14 and only trended toward normal at time of brace removal. Patients with VTE had a significantly higher median TAT level on day 10 to 14 (1.44 ng/ml; ng/ml; P ¼.012) and at the time the brace was removed (0.98 ng/ml; ng/ml; P ¼.035) compared to the non-vte group. AsshowninTable2,thesurgical patients experienced the highest rate of VTE. In the placebo arm of the study, mean and median TAT levels were consistently higher in the surgery group (n ¼ 106) than in the nonsurgery group (n ¼ 82) throughout the recovery period (P ¼.012; Figure 4). The highest TAT levels were found in the subgroup of surgically treated patients with VTE on day 10 to 14. The TAT levels Figure 4. Thrombin generation in surgical and nonsurgical patients during the recovery period. Compared to the conservatively treated group (n ¼ 82 placebo-treated patients), TAT levels were higher in the surgery group (n ¼ 106 placebo-treated patients) at all time points. The difference between groups was consistent and unchanged throughout the recovery period but did not reach significance. TAT indicates thrombin antithrombin complex; VTE, venous thromboembolism.
5 682 Clinical and Applied Thrombosis/Hemostasis 20(7) No thrombosis Thrombosis Tissue Factor; pg/ml TF; pg/ml Baseline Day Post Brace 20 Baseline Day Post brace Figure 7. Tissue factor in the VTE group of patients with leg trauma. Compared to the non-vte group (n ¼ 313), median TF levels were higher in the VTE group (n ¼ 52) at baseline (P ¼.003) and continued to remain higher through day 10 to 14 and at the postbrace time period. TF indicates tissue factor; VTE, venous thromboembolism. Figure 5. Tissue factor in patients with leg trauma during the recovery period. The median TF level was not elevated at the time of injury (n ¼ 183 placebo-treated patients); however, multiple patients had levels above the upper limit of normal. Certain patients had excessively high levels of >100 pg/ml. The median TF level did not significantly change over time. TF indicates tissue factor. TF pg/ml All pa ents Fracture Achilles Surgery No surgery tendon rupture Figure 6. Tissue factor in patients with leg trauma categorized by severity of injury. Many, but not all, patients with leg trauma (baseline samples on all patients) had elevated TF levels at the time of injury. Classified by type of injury, TF levels were higher in the fracture group than in the ATR group. Classified by type of treatment, TF levels tended to be higher in the nonsurgery group. TF indicates tissue factor; ATR, Achilles tendon rupture. reduced over time in both the groups. However, the difference between the surgically and nonsurgically treated groups at each time point did not reach significance due to the range of TAT values within each group. Tissue factor. Tissue factor (TF), an important activator of thrombin generation, was not elevated above normal (<35 pg/ml) at the time of injury in most patients as shown by median values (Figure 5). However, numerous patients had values higher than 90 pg/ml pushing the mean over the normal limit to 51.0 pg/ml, with excessively high TF levels in multiple patients as high as 200 and >500 pg/ml. The extremely high TF levels kept the mean consistent and over the normal range throughout the study period. Nonsignificant fluctuations in the median were noted from baseline to day 10 to 14 to postbrace time. Classified by severity of injury (ie, medical condition defined by type of injury and treatment), the TF levels were nonsignificantly higher in the fracture group (mean pg/ml and median pg/ml with an interquartile range of pg/ml; n ¼ 289) than in the ATR group (mean pg/ml and median pg/ml with an interquartile range of pg/ml; n ¼ 76) at baseline (Figure 6). Patients who underwent surgery prior to immobilization had a lower TF mean level (49.44 pg/ml) than patients who did not have surgery (58.10 pg/ml) but a similar median level. Because of a wide range of values, differences among all groups were not significant. Classified by VTE (n ¼ 52) or none (n ¼ 313), the patients who developed VTE had TF values higher than the normal limit (mean pg/ml; median pg/ml with an interquartile range of pg/ml) and far higher than the group that did not have VTE (mean pg/ml; median pg/ml with an interquartile range of pg/ml) at baseline (Figure 7; P ¼.003). The highest TF levels were found in patients with fractures who developed VTE. The higher TF levels in the group of patients with VTE held throughout the study period. The TF levels in both the groups did not significantly decline over time. Other biomarkers. The median PAI-1 level was within the normal range (<45 ng/ml) at the time of injury. The median PAI-1 level was slightly increased at day 10 to 14 (P <.001
6 Walenga et al 683 TAT; ng/ml Baseline Day Placebo Reviparin Post Brace TF; pg/ml Baseline Day Post Brace Placebo Reviparin Figure 9. Tissue factor in patients with leg trauma undergoing reviparin treatment. TF levels remained elevated in many patients throughout the study period regardless of treatment with the LMW heparin reviparin or placebo. Compared to placebo treatment (n ¼ 183), reviparin treatment (n ¼ 182) was associated only with slightly lower TF levels at day 10 to 14 and at the postbrace time (not significant). TF indicates tissue factor; LMW, low-molecular weight. Figure 8. Thrombin generation in patients with leg trauma undergoing reviparin treatment. TAT levels were rapidly normalized in nearly all patients treated with the LMW heparin reviparin (P <.001 vs baseline; n ¼ 182). Compared to placebo treatment (n ¼ 183), reviparin treatment was associated with lower TAT levels at day 10 to 14 (P ¼ 0.16) and at the postbrace time (P ¼.020). TAT indicates thrombin antithrombin complex; LMW, low-molecular weight. vs baseline; n ¼ 162) and at the postbrace time. By subgroup analysis, patients with VTE had higher PAI-1 levels (P ¼.01). The PAI-1 levels in the VTE group at baseline ranged from 7.2 to ng/ml (n ¼ 52) with a mean level of 43.8 ng/ml (median 33.9 ng/ml; ng/ml interquartile range). At day 10 to 14, PAI-1 levels in the VTE group increased to a mean of 49.0 ng/ml (median 43.9 ng/ml; ng/ml interquartile range). At the postbrace time period, the mean PAI-1 level was 47.0 ng/ml (median 40.5 ng/ml; ng/ml interquartile range) in the VTE group. Soluble thrombomodulin levels were not elevated above the upper limit of normal at baseline in any patient, and levels remained steady throughout the study period for all subgroups. Soluble P-selectin levels were elevated above the upper limit of normal (>40 ng/ml) for all patients at baseline with an increase at day 10 to 14 that sustained through the postbrace period. For patients with VTE (n ¼ 52), the baseline mean level was ng/ml (standard deviation), the day 10 to 14 mean level was ng/ml, and the postbrace mean level was ng/ml. In comparison, a control group that consisted of randomly selected non-vte patients (n ¼ 51) had a baseline mean level of ng/ml, a day 10 to 14 mean level of ng/ml, and a postbrace mean level of ng/ml. The increase that occurred at day 10 to 14 was not significant but was more evident in the VTE group. The HIT antibodies were detected in 6.6% of the total Plaster Cast study population, considering positivity at any time point of the study. The HIT antibody positivity was not significantly more frequent in the reviparin-treated group (n ¼ 12) than in the placebo-treated group (n ¼ 12). Of further interest, only 2 (8.3%) of 24 HIT antibody-positive patients, confirmed positive for HIT by a platelet function test ( 14 C-SRA), developed VTE (0.5% of the total population), and both were placebo-treated patients. Validation of Thrombogenesis Mechanism Thrombin antithrombin complex. Thrombin antithrombin complex levels in reviparin-treated patients (n ¼ 182) demonstrated an accelerated decrease from baseline to day 10 to 14 and remained low at the postbrace time (P <.001; Figure 8). Reviparin treatment normalized the TAT levels in nearly all patients from day 10 to 14 onward. For the reviparin-treated group at day 10 to 14, the median TAT level was 0.97 ng/ml ( ng/ml) with a mean level of 1.96 ng/ml, and at the postbrace time point, the median TAT level was 0.59 ng/ml ( ng/ml) with a mean level of 1.51 ng/ml. Levels were markedly lower in the reviparin-treated group than in the placebo-treated group where median/mean levels never reached levels as low as those in the reviparin group. The median TAT level in the placebo-treated group (n ¼ 183) at day 10 to 14 was 1.24 ng/ml ( ng/ml) with a mean of 3.55 ng/ml (P ¼.016 vs reviparin group). At the postbrace time, the median TAT was 0.89 ng/ml ( ng/ml) with a mean of 2.80 ng/ml (P ¼.020 vs reviparin group). These data are consistent with the decrease in VTE observed in the reviparin-treated patients compared to placebo-treated
7 684 Clinical and Applied Thrombosis/Hemostasis 20(7) patients (Tables 1 and 2), being particularly obvious in the patients who underwent surgery (Table 2). Tissue factor. Compared to the placebo-treated group, median TF levels were slightly lower in the reviparin-treated group throughout the treatment period but without statistical significance (Figure 9). The TF levels decreased but not significantly throughout the study period in both the reviparin- and placebotreated groups. Levels remained higher than normal in many patients throughout the study period. Mean levels did not differ between reviparin- and placebo-treated groups. Other biomarkers. Reviparin treatment was associated with an increase in TFPI level (P <.001). From an average TFPI level of 72 ng/ml in the placebo-treated patients throughout the study period, the reviparin-treated patient group had higher mean TFPI levels of 85 ng/ml on day 10 to 14 and 87 ng/ml at the postbrace time. PAI-1, soluble thrombomodulin, and soluble P-selectin levels were unaffected by reviparin treatment. Discussion Trauma and immobilization are independent risk factors for developing VTE. Even the simple trauma of isolated lower limb fractures or Achilles tendon injury where patients have functional immobility has a moderate risk of VTE. 10 Although most patients are at low risk of DVT/PE, these adverse events do occur. A 2007 clinical study not only confirmed past findings showing a 29% DVT prevalence in 49 patients with Achilles tendon injury treated surgically and a 39% DVT prevalence with 3 PEs in 46 patients treated nonoperatively but also was used to develop a scoring system to evaluate outcomes after treatment. 15 Experts continue to determine optimal treatment regimens 16 in an effort to promote universal practice. In the Plaster Cast clinical study, there was an overall 14% rate of VTE in otherwise healthy individuals who had lower leg injuries medically treated with plaster cast/brace immobilization. The VTE was determined to be associated with a hypercoagulable state characterized by a burst of TF release that sustained over the weeks of the immobilization period. Our findings in these patients with minor trauma were first reported in 2003 and were similar to the findings in a study of patients with major trauma published that same year. 20 Tissue factor is present in cellular membrane, and upon tissue damage/ activation its circulating levels are increased. It is one of the major mediators of coagulation system activation resulting in thrombin formation and fibrinogen conversion to fibrin. Although tissue factor levels were within the normal range for most patients, some patients had significantly elevated levels with a few having levels similar to those found in patients undergoing hip replacement surgery. 21 The induced hypercoagulable state in the Plaster Cast study patients was clearly defined by increased thrombin generation. The serine protease thrombin, once formed, complexes with the endogenous serine protease inhibitor antithrombin. The formed thrombin antithrombin complex circulates in blood of patients who sustain thrombotic disorders. In our study, thrombin generation was greater with fracture than softtissue injuries and greater with surgery than with conservative treatment (ie, no surgery). Of the biomarkers evaluated, tissue factor was determined to be the primary inducer of the hypercoagulable state in the Plaster Cast patient population. Tissue factor is found in endothelium, leukocytes, and activated platelets. 22 The PAI-1, found in endothelial cells and platelets, was slightly increased suggesting a potential fibrinolytic deficit that would add to the hypercoagulable state. Thrombomodulin, a surface receptor on endothelial cells, was not different from normal in any subgroup analysis comparing absolute levels between groups or between group changes from time point to time point. P-selectin, found in platelets and endothelial cells, was only slightly elevated. The findings on TF, PAI-1, and P-selectin suggest that in the Plaster Cast patients, there was some degree of vascular damage and platelet activation. Vascular damage per se may be downplayed due to the lack of thrombomodulin release. However, an upregulation of inflammation causing TF release from leukocytes cross-talking with activated platelets may be an important underlying mechanism that contributes to thrombin generation (TAT). Thrombin generation (from the injury) along with reduced fibrinolytic activation (from stasis due to edema causing venous compression and plaster cast/brace immobilization) provides the basis for thrombotic risk in patients with minor lower limb injuries. Long-term thromboprophylaxis with the LMW heparin reviparin greatly reduced thrombin generation (TAT). This was observed to the greatest extent within the first 2 weeks of reviparin treatment. Interestingly, LMW heparin treatment was not associated with a decrease in TF levels. Subgroup analysis showed that patients undergoing surgery to correct lower leg trauma, who receive no long-term thromboprophylaxis, are at highest risk to develop VTE. Long-term prophylaxis with LMW heparin benefitted patients in general regardless of type of injury or type of medical treatment. However, patients undergoing orthopedic surgery to correct their trauma benefited most from thromboprophylaxis. As the antithrombotic mechanism of LMW heparin is inhibition of FXa (with a component of thrombin inhibition), it would be of interest to consider a potential anticoagulant role for the new oral drugs that inhibit FXa, such as apixaban, edoxaban, and rivaroxaban, for thrombosis prophylaxis in patients with functional immobilization. In addition, inhibition of platelet activation and inflammation may also prove beneficial. After prolonged treatment for 5 to 6 weeks, only 2 cases of VTE in patients with functional HIT antibodies occurred (<1.0% of the study population). Both cases were in placebotreated patients. Antibody development may have been related to exposure to LMW heparin enoxaparin prior to enrollment in the study. Thus HIT was not an essential cause of VTE in this patient population. In addition to exposure to LMW heparin prior to enrollment in the study (determined not to be a confounding factor
8 Walenga et al 685 in the final analysis of the clinical trial data 13 ), there were several other limitations of this study. Baseline samples were collected on the day of study randomization not on the day of trauma. Other blood sample collection did not coincide with day of surgery or initiation of the thrombotic event. Individual data on trauma severity score were not collected. The size of the subgroups is small, and the variation in the results is relatively high. The data in Figures 3 and 7 include a mixed population of reviparin- and placebo-treated patients. The delay between conducting the study and final publication was only due to time constraints placed on the authors; however, the data was publicly released in a timely manner This study, strengthened by the inclusion of a placebo group, confirms that otherwise healthy individuals who incur lower leg injuries and plaster cast/brace immobilization are at risk of developing VTE, which is due to a sustained release of TF and possibly a fibrinolytic deficit leading to thrombin generation. The hypercoagulable state is greater with fractures than soft-tissue injuries and greater with surgery than conservative treatment. Treatment with LMW heparin during the immobilization phase is effective in reducing thrombin generation to a normal state, restoring the hemostatic balance. The mechanisms of VTE identified by this study support the inclusion of medical conditions relevant to lower limb injury in thrombosis risk scoring systems 23 and support the recommendation for thromboprophylaxis with LMW heparin in this patient population in consensus statements. 10 Acknowledgment Studies were supported by internal funding through Loyola University Chicago and no commercial funding was used. Authors Note The investigations reported herein were conducted in partial fulfillment of the dissertation for the medical doctoral degree of Ms Phoebe Kaiser through the University of Heidelberg. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. References 1. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Eng J Med. 1994;331(24): Rogers FB. Venous thromboembolism in trauma patients: a review. Surgery. 2001;130(1): O Malley KF, Ross SE. Pulmonary embolism in major trauma patients. J Trauma. 1990;30(6): Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep vein thrombosis in outpatients with injury of the lower limb. Haemostasis 1993;23(suppl 1): Kock HJ, Schmit-Neuerburg KP, Hanke J, Rudofsky G, Hirche H. Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. Lancet. 1995;346(8973): Hjelmstedt A, Bergvall U. Phlebographic study of the incidence of thrombosis in the injured and uninjured limb in 55 cases of tibial fracture. Acta Chir Scand. 1968;134(3): Abelseth G, Buckley RE, Pineo GE, Hull R, Rose MS. Incidence of deep-vein thrombosis in patients with fractures of the lower extremity distal to the hip. J Orthop Trauma. 1996; 10(4): Jorgensen PS, Warming T, Hansen K, et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study. Thromb Res. 2002;105(6): Barrett JA, Baron JA, Beach ML. Mortality and pulmonary embolism after fracture in the elderly. Osteoporos Int. 2003; 14(11): Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement. Int Angiol. 2013;32(2): Clagett GP, Anderson FA, Heit J, Levine MN, Brownell Wheeler H. Prevention of venous thromboembolism. Chest. 1995;108(4): 312S-334 S. 12. Nicolaides AN, Bergqvist D, Hull R, et al. Prevention of venous thromboembolism. International consensus statement. Int Angiol. 1997;16(1): Lassen MR, Borris LC, Nakov RL. Use of the low-molecular weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med. 2002;347(10): Lang T, Secic M. Comparing groups. How to report statistics in medicine. Philadelphia, USA: American College of Physicians; Nilsson-Helander K, Thomee R, Silbernagel KG, et al. The Achilles tendon Total Rupture Score (ATRS): development and validation. Am J Sports Med. 2007;35(3): SamamaCM,LecoulesN,KierzekG,etal.Comparisonof fondaparinux with low molecular weight heparin for venous thromboembolism prevention in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury. J Thromb Haemost. 2013;11(10): Kaiser PC. Coagulation parameters and heparin-induced IgG antibodies in patients after lower limb trauma requiring immobilization treated with low molecular weight heparin, reviparin a laboratory substudy of a placebo-controlled clinical trial. Dissertation for a medical doctoral degree, University of Heidelberg, Germany, Professor K. Andrassy, examiner. 18. Kaiser P, Prechel M, Hoppensteadt D, et al. Lower limb trauma is associated with a moderate risk of thrombosis caused by sustained release of tissue factor despite early functional mobilization. Thromb Haemost. 2003;1(suppl 1)(ISSN ):P Kaiser P, Prechel M, Hoppensteadt D, et al. Reviparin normalizes tissue factor pathway activation in patients with lower limb immobilization and is not associated with heparin antibody production. Thromb Haemost. 2003;1(suppl 1)(ISSN ):P2061.
9 686 Clinical and Applied Thrombosis/Hemostasis 20(7) 20. Meissner MH, Chandler WL, Elliott JS. Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability? J Trauma. 2003;54(2): Fedi S, Gori AM, Falciani M, et al. Procedure-dependence and tissue factor-independence of hypercoagulability during orthopedic surgery. Thromb Haemost. 1999;81(6): Panes P, Matus V, Saez CG, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor. Blood. 2007;109(12): Caprini J. Are you at risk for DVT? Caprini DVT Risk Score. Illinois State Medical Society. Accessed February 15, 2013.
The New England Journal of Medicine
USE OF THE LOW-MOLECULAR-WEIGHT HEPARIN REVIPARIN TO PREVENT DEEP-VEIN THROMBOSIS AFTER LEG INJURY REQUIRING IMMOBILIZATION MICHAEL R. LASSEN, M.D., LARS C. BORRIS, M.D., AND ROUMEN L. NAKOV, M.D., PH.D.
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationVenous Thromboembolism Prophylaxis in Foot and Ankle Surgery: A Literature Review
Open Access Publication Venous Thromboembolism Prophylaxis in Foot and Ankle Surgery: A Literature Review 1 by Stephanie L. Martin, DPM, Mark A. Hardy, DPM, FACFAS 2 The Foot & Ankle Journal 1 (5): 4 Venous
More informationThe Incidence of Venous Thromboembolism After Achilles Tendon Surgery in Patients
ORIGINAL ARTICLE The Incidence of Venous Thromboembolism After Achilles Tendon Surgery in Patients Receiving Thromboprophlaxis İlker Çolak, MD* Deniz Gülabi, MD* Engin Eceviz, MD* Bilgehan H Çevik, MD*
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationTop Ten Reasons For Failure To Prevent Postoperative Thrombosis
Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Joseph A. Caprini, MD, MS, FACS, RVT, FACCWS Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical
More informationJessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks
Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks 1. What is the most common cause of death in hospitalized patients? 1. Hospital-acquired infection 2. Pulmonary embolism 3. Myocardial infarction
More informationThromboembolic prophylaxis
.6 1 General topics Vein thrombosis in orthopedic trauma surgery 35 1.1 Introduction 35 1.2 History 35 2 Clinically important outcomes 35 2.1 Deep vein thrombosis (DVT) 35 2.2 Pulmonary embolism (PE) 35
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationAN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
More informationUpdates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis. By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan
Updates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan Objectives Describe the prevalence of PE and DVT as it relates
More informationProper Diagnosis of Venous Thromboembolism (VTE)
Proper Diagnosis of Venous Thromboembolism (VTE) Whal Lee, M.D. Seoul National University Hospital Department of Radiology 2 nd EFORT Asia Symposium, 3 rd November 2010, Taipei DVT - Risk Factors Previous
More informationTHROMBOEMBOLISM FOLLOWING ORTHOPAEDIC SURGERY
Department of Clinical Science and Education, Södersjukhuset Karolinska Institutet, Stockholm, Sweden THROMBOEMBOLISM FOLLOWING ORTHOPAEDIC SURGERY OUTCOME AND DIAGNOSTIC PROCEDURES AFTER PROPHYLAXIS IN
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationLars C. Borris, 1 Morten Breindahl, 2 Michael R. Lassen, 3 and Ákos F. Pap Introduction
Thrombosis Volume 11, Article ID 150750, 6 pages doi:10.1155/11/150750 Research Article Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationVTE in the Trauma Population
VTE in the Trauma Population Erik Peltz, D.O. February 11 th, 2015 * contributions from Eduardo Gonzalez, M.D. University of Colorado T-32 Research Fellow The problem. VTE - Scope of the Problem One of
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationVenous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital
Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital VTE is common and dangerous 5 VTE is Common VTE Incidence: 1.5 / 1000 per year
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationDVT and Pulmonary Embolus. Dr Piers Blombery BSc(Biomed), MBBS (Hons), FRACP, FRCPA Consultant Haematologist Peter MacCallum Cancer Centre
DVT and Pulmonary Embolus Dr Piers Blombery BSc(Biomed), MBBS (Hons), FRACP, FRCPA Consultant Haematologist Peter MacCallum Cancer Centre Overview Structure of deep and superficial venous system of upper
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationGetting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis
Reducing Harm Improving Healthcare Protecting Canadians VENOUS THROMBOEMBOLISM PREVENTION Getting Started Kit Section 2: Evidence-Based Appropriate VTE Prophylaxis January 2017 www.patientsafetyinstitute.ca
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationWith All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis
BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April
More information1. SCOPE of GUIDELINE:
Page 1 of 35 CLINICAL PRACTICE GUIDELINE: Venous Thromboembolism (VTE) Prevention Guideline: Thromboprophylaxis AUTHORIZATION: VP, Medicine Date Approved: May 17, 2012 Date Revised: Vancouver Coastal Health
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationPrevalence of Symptomatic Venous Thrombo-Embolism in Patients with Total Contact Cast for Diabetic foot Complications A Retrospective Case Series.
Prevalence of Symptomatic Venous Thrombo-Embolism in Patients with Total Contact Cast for Diabetic foot Complications A Retrospective Case Series. Dr R King, Miss GE Jackson, Mr SR Platt Wirral University
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationVenous Thromboembolism (VTE)
Venous Thromboembolism (VTE) Nursing A guide for patients and carers Contents Why do blood clots form in veins?... 1 How common is a deep vein thrombosis (DVT) or pulmonary embolus (PE)?... 2 How are DVTs/
More informationPage: 1 of 13. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Last Review Status/Date: March 2014 Page: 1 of 13 Compression Devices for Venous Description Patients undergoing major orthopedic surgery are at increased risk for venous thromboembolism (VTE). Patients
More informationThe Royal College of Emergency Medicine. VTE Risk in Lower Limb Immobilisation in Plaster Cast 2015/2016
The Royal College of Emergency Medicine Clinical Audits VTE Risk in Lower Limb Immobilisation in Plaster Cast Introduction 2015/2016 EXCELLENCE IN EMERGENCY MEDICINE A significant number of patients attend
More informationFactor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More informationHospital Acquired VTE: update on national guidance
Hospital Acquired VTE: update on national guidance Rebecca Chanda Consultant Pharmacist - Thrombosis and Haemostasis Guy s and St Thomas Hospitals NHS Foundation Trust Chair of the UK Clinical Pharmacy
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationJapanese Deep Vein Thrombosis
Japanese Deep Vein Thrombosis and Pulmonary Embolism after Total Knee Arthroplasty Artificial joint and cartilage implantation center, Kitasato institute hospital, Kitasato university Yasunori Tsukimura
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationVenous thromboembolism after total knee replacement or total hip replacement: what can be learnt from root-cause analysis?
TRAUMA AND ORTHOPAEDIC SURGERY Ann R Coll Surg Engl 2016; 98: 538 542 doi 10.1308/rcsann.2016.0202 Venous thromboembolism after total knee replacement or total hip replacement: what can be learnt from
More informationParameters influencing thromboprophylaxis management of a lower leg trauma treated with a cast/splint
Acta Orthop. Belg., 2008, 74, 672-677 ORIGINAL STUDY Parameters influencing thromboprophylaxis management of a lower leg trauma treated with a cast/splint Arne DECRAMER, Hans LOWYCK, Marc DEMUYNCK From
More informationCPT only copyright 2014 American Medical Association. All rights reserved. 12/23/2014 Page 66 of 593
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2015 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 16 December 1999 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL
More informationAdam Goldfarb, M.A., D.C., D.E.S.S. Introduction
Venous Thromboembolism Prophylaxis following Lower Extremity Orthopedic Surgery: A Review of the Biomedical Research Literature and Evidence-Based Policy in the United States. Adam Goldfarb, M.A., D.C.,
More informationVTE Prevention After Hip or Knee Replacement
This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource #340506 VTE Prevention After Hip or Knee Replacement The American College of
More informationVenous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials
Winner of the AAHKS Award Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials Greg A. Brown, MD, PhD The Journal of Arthroplasty Vol. 24
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationVenous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationDENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES:
More informationDr. Rami M. Adil Al-Hayali Assistant Professor in Medicine
Dr. Rami M. Adil Al-Hayali Assistant Professor in Medicine Venous thromboembolism: pulmonary embolism (PE) deep vein thrombosis (DVT) 1% of all patients admitted to hospital 5% of in-hospital mortality
More informationSymptomatic Venous Thromboembolism after Total Hip/Knee Replacement: A Population-based Taiwan Study
IMPROVING PATIENT SAFETY Preventing & Managing Venous Thromboembolism Session 8 Data Driving Strategies for VTE Prevention and Management 3/30/2012; 15.35-15.55 Symptomatic Venous Thromboembolism after
More informationincidence of cancer-associated thrombosis (CAT) is further increased by additional risk factors such as chemotherapeutic 2
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the ability of tumour cells to activate the
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationDiagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationLIMB COMPRESSION DEVICES FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS
PROPHYLAXIS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationHandbook for Venous Thromboembolism
Handbook for Venous Thromboembolism Gregory Piazza Benjamin Hohlfelder Samuel Z. Goldhaber Handbook for Venous Thromboembolism Gregory Piazza Cardiovascular Division Harvard Medical School Brigham and
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationExpanding the treatment options of Superficial vein thrombosis with Rivaroxaban
Expanding the treatment options of Superficial vein thrombosis with Rivaroxaban Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health
More informationTHROMBOSIS RISK FACTOR ASSESSMENT
Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationCHAPTER 2 VENOUS THROMBOEMBOLISM
CHAPTER 2 VENOUS THROMBOEMBOLISM Objectives Venous Thromboembolism (VTE) Prevalence Patho-physiology Risk Factors Diagnosis Pulmonary Embolism (PE) Management of DVT/PE Prevention VTE Patho-physiology
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationNational Quality Improvement Project 2018/2019 VTE Risk in Lower Limb Immobilisation Information Pack
National Quality Improvement Project 2018/2019 VTE Risk in Lower Limb Immobilisation Information Pack Introduction... 2 Methodology... 3 Flow of data searches to identify audit cases... 3 Data entry information...
More informationPharmacotherapy of Thrombo-embolic disorders
Pharmacotherapy of Thrombo-embolic disorders Intended Learning Objectives: 1. Define thromboembolic disorders 2. Identify risk factors, signs and symptoms of Venous thromboembolism. 3. Describe the processes
More informationIs Oral Rivaroxaban Safe and Effective in the Treatment of Patients with Symptomatic DVT?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 1-1-2013 Is Oral Rivaroxaban Safe and Effective
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Indication: Treatment of blood clots Blood clots in the large veins of the legs, known as deep vein thrombosis (DVT), are a common
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationPrevention of Venous Thromboembolism in Department of Veterans Affairs Hospitals
ORIGINAL RESEARCH Prevention of Venous Thromboembolism in Department of Veterans Affairs Hospitals Jerome Herbers, MD, MBA Susan Zarter, BSN Department of Veterans Affairs, Office of the Inspector General,
More information